

# Setting the standard

## ImmunoCAP™ Specific IgE Peanut Allergen Components\*

Use this guide to interpret ImmunoCAP Allergen Component test results and unlock a broader understanding of a patient’s allergic sensitization, allowing for a more comprehensive management plan.<sup>1</sup>

### Testing with peanut allergen components can help to:<sup>1-19</sup>


- Assess risk for systemic allergic reactions
- Identify cross-reactivity
- Optimize diagnosis and management

77%

**of patients sensitized to peanut may not be at risk for a systemic reaction<sup>2</sup>**

Pinpointing exactly which protein an individual is sensitized to may help determine the risk for a systemic reaction.<sup>1-12</sup>

### Risk stratification<sup>2-12</sup>



### Characteristics of individual proteins<sup>3,4,6,9</sup>

CCD	Profilin	PR-10	LTP	Storage Protein
Does not usually provoke clinical reactions	Sensitization is usually asymptomatic	Labile to heat and digestion	Stable to heat and digestion	Stable to heat and digestion
Highly cross-reactive (pollen, plant food, venoms)	Abundant in nature	Mainly local reactions	Local and systemic reactions	Associated with systemic reactions
	Cross-reactive with pollen	Cross-reactive with birch pollen	Cross-reactive with plant foods and pollens	Indicates primary sensitization

## Management considerations<sup>2,5,6,13-19</sup>

CCD, Profilin, PR-10 MUXF3, Bet v 2 <sup>†</sup> , Ara h 8	LTP Ara h 9	Storage Proteins Ara h 1, Ara h 2, Ara h 3, Ara h 6	
+/-	+/-	+	<p><b>If clinical symptoms are present with exposure to peanuts</b>, high probability of clinical peanut allergy and possibility for severe, systemic reactions. Consider the following:</p> <ul style="list-style-type: none"> <li>• Patient likely to react to oral food challenge (OFC)</li> <li>• Other potential co-sensitizations (e.g. tree nuts and seeds)</li> <li>• Prescribing epinephrine auto-injector</li> <li>• Inform family, colleagues, and teachers of the allergy and have a plan</li> </ul>
+/-	+	-	<p><b>If clinical symptoms are present with exposure to peanuts</b>, consider the following:</p> <ul style="list-style-type: none"> <li>• Systemic and local reaction such as oral allergy syndrome (OAS) are possible</li> <li>• Potential cross-reactivity to other LTP containing foods (e.g. peach, tree nuts, wheat) and pollens (e.g. weed and tree)</li> <li>• Prescribing epinephrine auto-injector</li> </ul>
+	-	-	<p><b>If there are no symptoms with peanut exposure</b>, or if symptoms are localized to only the oral cavity, primary peanut allergy and severe reactions are less likely. Consider the following:</p> <ul style="list-style-type: none"> <li>• OFC with a specialist may be recommended</li> </ul>

Note: As in all diagnostic testing, any diagnosis or treatment plan must be made by the clinician based on test results, individual patient history, the clinician's knowledge of the patient, as well as their clinical judgment. Patients can be sensitized to more than one allergen component.<sup>1</sup>

**Whole allergens consist of numerous allergen components.** A positive whole allergen sensitization with negative allergen component sensitization may mean a patient is sensitized to a component that is not yet available for testing. Consider a patient's clinical history and if an OFC with a specialist may be warranted.

\* Official product names of allergen components mentioned within this document: ImmunoCAP Allergen f13, Peanut; ImmunoCAP Allergen c214, Allergen component MUXF3 CCD, Bromelain; ImmunoCAP Allergen f422, Allergen Component rAra h 1 Peanut; ImmunoCAP Allergen f423, Allergen Component rAra h 2 Peanut; ImmunoCAP Allergen f424, Allergen Component rAra h 3 Peanut; ImmunoCAP Allergen f447, Allergen Component rAra h 6 Peanut; ImmunoCAP Allergen f352, Allergen component rAra h 8 PR-10, Peanut; ImmunoCAP Allergen f427, Allergen component rAra h 9 LTP, Peanut; ImmunoCAP Allergen t216, Allergen component rBet v 2 Profilin, Birch  
<sup>†</sup> Surrogate markers for profilin Phl p 12, Bet v 2, Pru p 4

### References

1. Kleine-Tebbe J, Jappe U. Molecular allergy diagnostic tests: development and relevance in clinical practice. *Allergologie select.* 2017;1 (2):169-1893.
2. Nicolaou N, Poorafshar M, Murray C, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. *J Allergy Clin Immunol.* 2010;125(1):191-197.
3. Bradshaw N, A Clinical Reference Guide to Molecular Allergy. Go Molecular! Molecular Allergy –The Basics, 2014.
4. Katelaris CH: Food allergy and oral allergy or pollen-food syndrome. *Curr Opin Allergy Clin Immunol* 2010, 10:246–251.
5. Asamoj A, Nilsson C, Lidholm J, et al. Peanut component Ara h 8 sensitization and tolerance to peanut. *J Allergy Clin Immunol.* 2012;130(2):468-472.
6. Nucera E, et al. Hypersensitivity to major panallergens in a population of 120 patients. *Postepy Dermatol Alergol.* 2015 Aug; 32(4): 255–261.
7. Mittag D, Akkerdaas J, Ballmer-Weber BK, et al. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. *J Allergy Clin Immunol.* 2004;114(6):1410-1417.
8. Lauer I, Dueringer N, Pokoj S, et al. The nonspecific lipid transfer protein, Ara h 9, is an important allergen in peanut. *Clin Exp Allergy.* 2009;39(9):1427-1437.
9. Sastre J: Molecular diagnosis in allergy. *Clin Exp Allergy* 2010, 40:1442–1460.
10. Movérare R, Ahlstedt S, Bengtsson U, et al. Evaluation of IgE antibodies to recombinant peanut allergens in patients with reported reactions to peanut. *Int Arch Allergy Immunol.* 2011;156(3):282-290.
11. Peeters KA, Koppelman SJ, van Hoffen E, et al. Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? *Clin Exp Allergy.* 2007;37(1):108-115.
12. Asamoj A, Movérare R, Östblom E, et al. IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. *Allergy.* 2010;65(9):1189-1195.
13. Dang, Thanh, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara H 2. *J Allergy Clin Immunol.* 2012;129(4):1056-1063.
14. Nicolaou, N, et al. Quantification of specific IgE to whole peanut extract and peanut components in predication of peanut allergy. *J Allergy Clin Immunol.* 2011:1-2.
15. Vereda, A, et al. Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. *J Allergy Clin Immunol.* 2010;3(2):1-5.
16. Lange L, Beyer K, Kleine-Tebbe J. Benefits and limitations of molecular diagnostics in peanut allergy. *Allergo J Int.* 2014;23:158–63.
17. Pedrosa, M, et al. Utility of specific IgE to Ara h 6 in peanut allergy diagnosis. *Ann Allergy Asthma Immunol.* 2015;115:108-112.
18. van der Valk, JP, et al. Mono-sensitisation to peanut component Ara h 6: a case series of five children and literature review. *Eur J Pediatr.* 2016;175:1227–1234.
19. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. *J Allergy Clin Immunol.* 2014;133(2):291-307.